Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
Infectious disease: another reason to try Veganuary for the NHS
30 January 2025
We dust off last year’s model to consider the potential savings to the NHS from more people going vegan, with a focus on COVID-19.
Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
12 November 2024
More collaborative initiatives are taking place among regulatory agencies, health technology assessment (HTA) bodies and between regulatory and HTA agencies at national and regional levels.
Around The World in HTAs: Thailand – An Ever-Evolving Policy Tool
9 September 2024
In our Around the World in HTAs insight series we shed light on HTA successes and challenges around the world. In this edition, Sarin KC, Manit Sittimart, Chittawan Poonsiri, Yi Wang, and Simon Brassel take us to Thailand.
Unlocking the Value of Combination Therapies
9 July 2024
Combination therapies (CTs) merge treatments with different mechanisms of action to achieve greater clinical benefits than the individual components alone. CTs are increasingly being used in oncology.
Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
26 June 2024
Our literature review suggests that there are more than 100 inequalities impacting on people living with dementia and their carers across multiple characteristics, circumstances, and in various parts of the health and care system. However, the current low availability and quality of data is a major barrier to accurately measuring these inequalities. With the expectation that 1 in 2 people will be affected by dementia during their lifetime, there is a pressing need for further research to inform future policy, research, and service interventions.
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
Combination therapies can provide effective treatment options and improve patient outcomes. However, there are significant barriers to patient access to combination therapies, including the prevailing pricing models used in Europe.
Around the World in HTAs: United States – Making HTA Great Again
11 June 2024
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Chris Sampson and Dan Ollendorf take us to the United States.
How Have HTA Agencies Evolved Their Methods Over Time?
29 April 2024
The many changes in Health Technology Assessment (HTA) methods and processes over time, are a challenge to navigate let alone stay abreast of. This report explores the breadth of variation in past and current positioning of HTA agencies in 14 countries, on five key methodological topics: discount rates, modifiers, patient involvement, real-world evidence (RWE), and surrogate endpoints.
Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report
18 April 2024
Our new report examines the promise of prevention in healthcare and provides six key recommendations that could usher in a new era of optimised prevention.